Arax Advisory Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Arax Advisory Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.3K	Buy	2,071 +2,066	+41,320%	+$37.5K	﹤0.01%	3450
2026 Q1	$93	Buy	+5	New	+$83	﹤0.01%	3621
2025 Q4	–	Sell	-82	Closed	-$588	–	4362
2025 Q3	$588	Buy	+82	New	+$4.27K	﹤0.01%	3348

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arax Advisory Partners's MLTX Position: Q2 2026 in Review

Arax Advisory Partners increased its MoonLake Immunotherapeutics (MLTX) stake by 41,320% in Q2 2026, buying an estimated $37.5K and bringing the position to 2,071 shares worth $40.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3450.

Arax Advisory Partners first reported a position in MLTX in Q3 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Arax Advisory Partners held 2,071 shares of MoonLake Immunotherapeutics worth $40.3K as of Q2 2026.
Arax Advisory Partners bought 2,066 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $37.5K.
MoonLake Immunotherapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3450 holding.
Arax Advisory Partners first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 3 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.